Company Highlights May 6, 2026 Integrated Nanotherapeutics will be exhibiting at Web Summit 2026, May 11-14, in Vancouver, BC. Apr 20, 2026 Integrated Nanotherapeutics will be speaking at the 21st Immunology of Diabetes Society Congress & Australian Islet Study Group Meeting (IDS) 2026, Apr 20-24, in Brisbane, Australia. Mar 18, 2026 Integrated Nanotherapeutics Secures Genome Canada GAPP Funding to Advance Multi-Cargo mRNA/LNP Therapy for Type 1 Diabetes Toward the Clinic Mar 3, 2026 Integrated Nanotherapeutics will be speaking at the 9th Antigen-Specific Immune Tolerance Summit (ASIT) 2026 Annual Meeting, Mar 3-6, in Boston. Jan 12, 2026 Integrated Nanotherapeutics will be attending Biotech Showcase 2026 during JPM Week, Jan 13 – 15, in San Francisco. Feb 25, 2025 Integrated Nanotherapeutics will be speaking at the 8th Antigen-Specific Immune Tolerance Summit (ASIT) 2025, Feb 25 – 27, in Boston. Jan 13, 2025 Integrated Nanotherapeutics will be attending Biotech Showcase 2025 during JPM Week, Jan 13 – 15, in San Francisco. Sep 9, 2024 Integrated Nanotherapeutics and Breakthrough T1D Collaborate to Advance Development of an Immune Tolerizing Therapeutic to Treat Type 1 Diabetes. Jun 11, 2024 Integrated Nanotherapeutics is presenting T1D preclinical data at the Federation of Clinical Immunology Societies (FOCIS) 2024 Annual Meeting, June 18 – 21, in San Francisco.
